Liquidia and PATH partnered to conduct preclinical proof-of-concept studies of a pneumococcal vaccine using Liquidia's Particle Replication In Non-Wetting Templates (PRINT) platform

Liquidia Technologies Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

PATH .

U.S. / Non-Profit or Major Disease Foundation

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced